On Monday, Eli Lilly and Co. has been provided additional perspective in response to Amylin Pharmaceuticals Inc.'s lawsuit. Lilly has been previously alleged of not using commercially reasonable efforts to support the success of Byetta, an exenatide injection, and Bydureon, an extended-release for injectable suspension. Its hearing is being conducted in US court.

According to the report of Eli Lilly's Chief executive, a patient who had been out on trials of the company's experimental Alzheimer's disease drug solanezumab had developed swelling in brain. Although this swelling is known to be a temporary one, but the fact behind this illness is still not confirmed. The patient was actually consuming the Lilly drug or a placebo needs to be revealed.

U. S. advisory panel on Wednesday dismissed Eli Lilly & Co (LLY. N) request to approve its drug liprotamase (Sollpura), a pancreatic enzyme product for cystic fibrosis and other diseases that cause pancreatic insufficiency.

An advisory panel of the Food and Drug Administration had voted 9-to-3 against drug, liprotamase manufactured by a unit of Eli Lilly & Co. saying that its medicinal effectiveness is not worth approval. Also, the panel voted 7-to-4 for the less benefits of the drug in comparison to risks it poses.

Health care reforms charges are witnessed to assist squeeze Eli Lilly and Co.'s first-quarter profit by nearly 5 percent thereby offsetting strong sales growth attributed to its some of its top-selling drugs.

There is good news for patients suffering from locally advanced or metastatic non-small cell lung cancer! Alimta, Eli Lilly & Co.'s chemotherapy, has managed to pass the second of the third step, by earning the funding from United Kingdom's National Health Service.

Merck, Eli Lilly and Pfizer announced a plan to create a not-for-profit company in Asia to speed up Cancer research and treatments.

The Asian Cancer Research Group has set an example of collaboration among major drug companies to combine resources and expertise to rapidly increase the knowledge of a disease and the disease process.

The Scottish Medicines Consortium has announced the approval for the use of Eli Lilly's Alimta for lung cancer and Janssen-Cilag's Stelara for psoriasis on the National Health Service.

Bristol-Myers Squibb claims to witness stronger-than-expected fourth quarter earnings, backed by sharply lower taxes and cost cuts, and augurs its 2010 earnings in line with Wall Street expectations, and Eli Lilly, on the other hand, has also seen a profit over the period.

The U. S. Food and Drug Administration (FDA) on Friday approved Eli Lilly's blood thinner Effient, but the drug is required to carry the agency's sternest warning due to its bleeding risks.